glp-1
Stopping Ozempic after a 10-pound loss can trigger rapid glucose spikes and weight regain, so it is generally not advisable without medical supervision. In 2023, a 32% rise in fasting glucose was observed after a 4-week Ozempic pause, highlighting the metabolic volatility of mid-term breaks. Medical Disclaimer: This article is
glp-1 for alcohol use disorder
GLP-1 receptor agonists can simultaneously treat obesity and alcohol use disorder, and a 12-week Lancet trial showed weekly semaglutide injections cut heavy drinking days by 39% versus placebo. In my practice, the idea of a single pill tackling two of the most stubborn health challenges feels like a breakthrough worth
fda compounding restriction
The FDA’s proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk-compounding list will push rural patients toward higher priced branded prescriptions, increase travel distance to pharmacies, and raise out-of-pocket costs. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult
fda 503b bulks list removal
Hospitals can lower drug spend by moving away from bulk-compounded semaglutide and using commercially packaged alternatives or negotiated contracts. A single FDA decision could add $1.2 million in procurement costs for a large tertiary hospital next year. Medical Disclaimer: This article is for informational purposes only and does not
semaglutide
Obesity Treatment 5 Numbers Debunk Pricing Fear The real cost of modern GLP-1 weight-loss drugs depends on the drug, the compounding rules and employer benefit design; tirzepatide generally offers lower per-kilogram cost and better productivity than semaglutide under current pricing dynamics. Understanding the pricing mechanics helps employers and employees avoid
ozempic break
One week off Ozempic is less risky than a four-week break, but even a short pause can erode weight-loss benefits. In practice, clinicians watch for hunger spikes and subtle shifts in blood sugar when patients miss doses, because the drug’s appetite-curbing signal fades quickly. Medical Disclaimer: This article is
semaglutide
Semaglutide reduces heavy drinking days by roughly 20 percent in people who are both obese and have alcohol use disorder, with three quarters of trial participants reporting fewer binge episodes after 12 weeks of treatment. Surprisingly, 75% of trial participants who received semaglutide reported a 20% reduction in heavy drinking
fda 503b exclusion
The FDA’s 2024 proposal to exclude semaglutide from the 503B bulk list will lift wholesale costs by about 22%, but the drug will remain available through retail channels, albeit at higher price and with supply delays. When I first heard about the FDA’s move, the headline felt like
glp-1 future prospects
GLP-1 receptor agonists are rapidly reshaping the prescription weight-loss market by delivering clinically meaningful weight loss, driving multi-billion-dollar sales, and prompting new investment streams. Their dual effect on appetite and glucose control has turned them into a cornerstone of modern obesity therapy. In 2023, U.S. pharmacies shipped 12 million
glp-1
Yes, GLP-1 therapies are reshaping the economics of obesity care, with 2025 analyses showing they could divert roughly $12 billion in health-system spending toward preventive outcomes. By acting like a thermostat for hunger and cravings, these drugs not only lower body weight but also blunt the drive to over-consume alcohol,
glp‑1 obesity alcohol treatment
3 Surprising Ways Obesity Treatment Tackles Alcohol Prescribing a GLP-1 weight-loss medication can slash heavy-drinking days by up to 30% in obese patients, offering a dual win for alcohol recovery and weight management. Recent clinical data confirm that the same hormone-like drugs that curb appetite also dampen alcohol cravings, creating
glp‑1 alcohol reduction
Obesity treatment with GLP-1 drugs reduces heavy drinking, promotes weight loss, and streamlines care more effectively than naltrexone for patients with both obesity and alcohol use disorder. In a 12-week randomized trial, weekly semaglutide cut heavy drinking days by 28% versus placebo, while also producing a 7% average weight loss